BioPharma Dive September 12, 2024
Bicara Therapeutics, Zenas BioPharma and MBX Biosciences all priced initial public offerings Thursday in the busiest week for biotech stock sales since February.
Three drug startups collectively raised more than $700 million in initial public offerings Thursday, a flurry of activity after a largely fallow summer in which few biotechnology companies made the jump to public markets.
Cancer biotech Bicara Therapeutics secured $315 million in the third-largest IPO of the year, according to BioPharma Dive data. Autoimmune drug developer Zenas BioPharma followed with a $225 million stock sale, while MBX Biosciences, which is studying endocrine and metabolic conditions including obesity, raised $163 million.
All three met projections they set the past few weeks. Bicara hiked its offering size by 25%...
Today's Sponsors
Today's Sponsor